PLUR Quote, Financials, Valuation and Earnings

IM Cannabis Corp. has a net margin of -1940.51% compared to Pluri, Inc.'s net margin of -27.9%. Pluri, Inc.'s return on equity of -5662.45% beat IM Cannabis Corp.'s return on equity of -135.96%.

Pluri, Inc. has a consensus price target of $12.00, signalling upside risk potential of 250.88%. On the other hand IM Cannabis Corp. has an analysts' consensus of -- which suggests that it could grow by 254.63%. Given that IM Cannabis Corp. has higher upside potential than Pluri, Inc., analysts believe IM Cannabis Corp. is more attractive than Pluri, Inc..

Pluri, Inc. has a beta of 0.575, which suggesting that the stock is 42.476% less volatile than S&P 500. In comparison IM Cannabis Corp. has a beta of 2.180, suggesting its more volatile than the S&P 500 by 117.961%.

Pluri, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IM Cannabis Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pluri, Inc. pays -- of its earnings as a dividend. IM Cannabis Corp. pays out -- of its earnings as a dividend.

Pluri, Inc. quarterly revenues are $316K, which are smaller than IM Cannabis Corp. quarterly revenues of $10.1M. Pluri, Inc.'s net income of -$6.1M is lower than IM Cannabis Corp.'s net income of -$2.8M. Notably, Pluri, Inc.'s price-to-earnings ratio is -- while IM Cannabis Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pluri, Inc. is 18.70x versus 0.16x for IM Cannabis Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IR-Med, Inc. has a net margin of -1940.51% compared to Pluri, Inc.'s net margin of --. Pluri, Inc.'s return on equity of -5662.45% beat IR-Med, Inc.'s return on equity of --.

Pluri, Inc. has a consensus price target of $12.00, signalling upside risk potential of 250.88%. On the other hand IR-Med, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Pluri, Inc. has higher upside potential than IR-Med, Inc., analysts believe Pluri, Inc. is more attractive than IR-Med, Inc..

Pluri, Inc. has a beta of 0.575, which suggesting that the stock is 42.476% less volatile than S&P 500. In comparison IR-Med, Inc. has a beta of 2.696, suggesting its more volatile than the S&P 500 by 169.614%.

Pluri, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IR-Med, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pluri, Inc. pays -- of its earnings as a dividend. IR-Med, Inc. pays out -- of its earnings as a dividend.

Pluri, Inc. quarterly revenues are $316K, which are larger than IR-Med, Inc. quarterly revenues of --. Pluri, Inc.'s net income of -$6.1M is lower than IR-Med, Inc.'s net income of -$701K. Notably, Pluri, Inc.'s price-to-earnings ratio is -- while IR-Med, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pluri, Inc. is 18.70x versus -- for IR-Med, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

BiomX, Inc. has a net margin of -1940.51% compared to Pluri, Inc.'s net margin of --. Pluri, Inc.'s return on equity of -5662.45% beat BiomX, Inc.'s return on equity of -160.84%.

Pluri, Inc. has a consensus price target of $12.00, signalling upside risk potential of 250.88%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 8747.01%. Given that BiomX, Inc. has higher upside potential than Pluri, Inc., analysts believe BiomX, Inc. is more attractive than Pluri, Inc..

Pluri, Inc. has a beta of 0.575, which suggesting that the stock is 42.476% less volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.

Pluri, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pluri, Inc. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.

Pluri, Inc. quarterly revenues are $316K, which are larger than BiomX, Inc. quarterly revenues of --. Pluri, Inc.'s net income of -$6.1M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, Pluri, Inc.'s price-to-earnings ratio is -- while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pluri, Inc. is 18.70x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Raphael Pharmaceutical, Inc. has a net margin of -1940.51% compared to Pluri, Inc.'s net margin of --. Pluri, Inc.'s return on equity of -5662.45% beat Raphael Pharmaceutical, Inc.'s return on equity of --.

Pluri, Inc. has a consensus price target of $12.00, signalling upside risk potential of 250.88%. On the other hand Raphael Pharmaceutical, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Pluri, Inc. has higher upside potential than Raphael Pharmaceutical, Inc., analysts believe Pluri, Inc. is more attractive than Raphael Pharmaceutical, Inc..

Pluri, Inc. has a beta of 0.575, which suggesting that the stock is 42.476% less volatile than S&P 500. In comparison Raphael Pharmaceutical, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pluri, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Raphael Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pluri, Inc. pays -- of its earnings as a dividend. Raphael Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Pluri, Inc. quarterly revenues are $316K, which are larger than Raphael Pharmaceutical, Inc. quarterly revenues of --. Pluri, Inc.'s net income of -$6.1M is lower than Raphael Pharmaceutical, Inc.'s net income of -$255K. Notably, Pluri, Inc.'s price-to-earnings ratio is -- while Raphael Pharmaceutical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pluri, Inc. is 18.70x versus -- for Raphael Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.